

4basebio PLC

("4basebio" or the "Company")

Result of Extraordinary General Meeting

Cambridge, UK, 10 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that all of the resolutions proposed at its Extraordinary General Meeting held earlier today were duly passed.

For further enquiries, please contact:

4basebio PLC	+44 (0)12 2396 7943
Dr. Heikki Lanckriet, CEO	
Cairn Financial Advisers LLP (Nominated Adviser)	+44 (0)20 7213 0880
Jo Turner / Sandy Jamieson / Ed Downes	
Cavendish Capital Markets Limited (Joint Broker)	+44 (0)20 7220 0500
Geoff Nash / Nigel Birks	
RBC Capital Markets (Joint Broker)	+44 (0)20 7653 4000
Kathryn Deegan / Matthew Coakes	

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company's objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
